Get the Stockscreener App
2.87
5.59%
-0.17
After Hours:
2.84
-0.03
-1.05%
Aquestive Therapeutics Inc stock is traded at $2.87, with a volume of 1.25M.
It is down -5.59% in the last 24 hours and up +8.30% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.04
Open:
$2.99
24h Volume:
1.25M
Relative Volume:
0.80
Market Cap:
$300.57M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-7.8824
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-10.59%
1M Performance:
+8.30%
6M Performance:
-38.68%
1Y Performance:
-34.47%
1-Day Range:
$2.82
$2.99
1-Week Range:
$2.76
$3.20
52-Week Range:
$2.24
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.87 | 300.57M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
159.61 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.45 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.85 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
307.36 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive completes marketing application for Anaphylm in U.S. - MSN
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com
Aquestive Therapeutics Announces Positive Topline PK - GlobeNewswire
Revolutionary Allergy Treatment Proves Safe in Children: Game-Changing Alternative to EpiPen Heads to FDA - Stock Titan
Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive stock falls amid Libervant approval, Anaphylm update - MSN
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Lake Street Capital Lowers Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00 - Defense World
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners - TipRanks
New York State Common Retirement Fund Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating - TipRanks
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com UK
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates - Investing.com
Aquestive Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued - Marketscreener.com
Aquestive Therapeutics misses Q4 estimates, shares fall - Investing.com India
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Nasdaq
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c) - TipRanks
Aquestive Therapeutics misses Q4 estimates, shares fall By Investing.com - Investing.com South Africa
Aquestive Therapeutics Initiates Anaphylm NDA Filing Process - TipRanks
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):